{"gene":"MEN1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1998,"finding":"Menin is located primarily in the nucleus, with at least two independent nuclear localization signals (NLS) both located in the C-terminal fourth of the protein, as determined by immunofluorescence, subcellular fractionation Western blotting, and GFP-tagging of deletion constructs.","method":"Immunofluorescence, Western blotting of subcellular fractions, epitope-tagged GFP deletion constructs","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (immunofluorescence, fractionation, GFP deletion mapping) in a single focused study, replicated by subsequent studies","pmids":["9465067"],"is_preprint":false},{"year":2000,"finding":"Zebrafish menin binds both human and mouse JunD and represses JunD-induced transcription, demonstrating that the JunD-binding and transcriptional repression function of menin is evolutionarily conserved.","method":"Protein binding assay, transcriptional reporter assay in zebrafish","journal":"Mammalian genome : official journal of the International Mammalian Genome Society","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional binding and reporter assay in an ortholog system, single lab but two methods","pmids":["10818209"],"is_preprint":false},{"year":2006,"finding":"Men1 excision in mouse embryonic fibroblasts accelerates G0/G1 to S phase entry, accompanied by increased CDK2 activity and decreased expression of CDK inhibitors p18(Ink4c) and p27(Kip1). Complementation with wild-type menin represses S-phase entry. In vivo, Men1 excision in pancreatic islets increases proliferation within 7 days.","method":"Conditional Men1 knockout in MEFs (Cre-lox), cell cycle analysis, CDK2 kinase assay, in vivo tamoxifen-inducible Men1 deletion in pancreatic islets with BrdU labeling","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro and in vivo loss-of-function with specific molecular readouts (CDK2 activity, p18/p27 expression, cell cycle), complementation rescue performed","pmids":["16740708"],"is_preprint":false},{"year":2006,"finding":"Genetic epistasis in mice shows that p18(Ink4c), but not p27(Kip1), functionally collaborates with Men1 to suppress neuroendocrine organ tumors. p18(-/-);Men1(+/-) mice develop tumors at accelerated rates with increased Rb phosphorylation at both CDK2 and CDK4/6 sites, and the remaining wild-type Men1 allele is often retained in p18-null compound tumors, indicating functional redundancy between p18 and Men1 in the same pathway.","method":"Double-mutant mouse epistasis, tumor incidence analysis, Rb phosphorylation western blotting, LOH analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo with molecular pathway validation (Rb phosphorylation), replicated concept in lung tumors (PMID 17409423)","pmids":["17145768"],"is_preprint":false},{"year":2007,"finding":"p18(Ink4c) functionally collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers; bronchioalveolar stem cells are further expanded in p18(-/-);Men1(+/-) compound mice compared to single mutants, and Rb phosphorylation at CDK2 and CDK4/CDK6 sites is significantly increased.","method":"Double-mutant mouse model, lung tumor characterization, Rb phosphorylation analysis, bronchioalveolar stem cell quantification","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with molecular pathway validation, replicates collaboration between p18 and Men1 seen in endocrine tissues","pmids":["17409423"],"is_preprint":false},{"year":2013,"finding":"Menin directly interacts with PRMT5, a negative regulator of gene transcription. Menin recruits PRMT5 to the Gas1 gene promoter, increases repressive histone arginine symmetric dimethylation (H4R3m2s), and suppresses Gas1 expression, thereby epigenetically suppressing Hedgehog signaling. MEN1 disease-related menin mutants show reduced PRMT5 binding and fail to impart the H4R3m2s mark at the Gas1 promoter.","method":"Co-immunoprecipitation, ChIP assay, histone methylation analysis, luciferase reporter, pharmacologic Hedgehog inhibition in MEN1 mouse tumors, mutant menin binding analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP, functional reporter, disease mutant validation, and pharmacologic rescue in vivo — multiple orthogonal methods","pmids":["23580576"],"is_preprint":false},{"year":2014,"finding":"CDK4, but not CDK2, is required for MEN1-dependent tumorigenesis in pituitary and pancreatic islets. Men1(+/-);Cdk4(-/-) mice do not develop tumors and remain hypoplastic, while Men1(+/-);Cdk2(-/-) mice show normal tumorigenesis. CDK4 knockdown in INS-1 insulinoma cells inhibits glucose-stimulated cell cycle progression with decreased RB phosphorylation at Ser780, while CDK2 knockdown has minimal effect.","method":"Double-mutant mouse epistasis, tumor incidence analysis, LOH analysis, CDK4/CDK2 knockdown in insulinoma cells, RB phosphorylation western blotting","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in two cell types in vivo, confirmed by cell-line RNAi with phospho-specific RB readout, multiple orthogonal methods","pmids":["24531709"],"is_preprint":false},{"year":2010,"finding":"Alpha cell-specific Men1 ablation in mice leads to the transdifferentiation of glucagon-expressing cells into insulinoma cells, demonstrating that menin regulates the plasticity of differentiated pancreatic alpha cells in vivo. Genetic cell lineage tracing confirmed that insulinoma cells were directly derived from glucagon-expressing cells.","method":"Conditional Men1 knockout (GluCre-loxP), genetic cell lineage tracing, immunohistochemistry, transcription factor expression analysis","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with genetic lineage tracing providing direct mechanistic evidence of cell fate change","pmids":["20138042"],"is_preprint":false},{"year":2016,"finding":"Loss of menin activates DNMT1 by activating retinoblastoma-binding protein 5 (Rbbp5), leading to global DNA hypermethylation. This aberrant methylation inactivates Sox regulatory genes and aberrantly activates Wnt/β-catenin signaling. Demonstrated in MEN1 parathyroid tumors, Men1 knockout mice, and Men1-null MEF cell lines.","method":"Genome-wide methylation analysis, Men1 KO mouse and MEF cell lines, DNMT1 activity assay, Rbbp5 pathway analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide methylation plus mechanistic pathway analysis in multiple model systems, single lab","pmids":["26871472"],"is_preprint":false},{"year":2020,"finding":"Men1 loss in the exocrine pancreas causes increased injury and impaired regeneration following acute caerulein-induced pancreatitis. Men1 protein is stabilized in response to pancreatic insult. Loss of Men1 is associated with overexpression of pro-inflammatory JunD target genes, suggesting menin suppresses JunD activity in the exocrine pancreas. Men1 loss also significantly accelerates mutant Kras-dependent pancreatic oncogenesis.","method":"Conditional Men1 KO mouse model, caerulein pancreatitis model, KrasG12D compound mouse model, Men1 protein stability assay, JunD target gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with mechanistic pathway readout (JunD targets), protein stabilization assay, and oncogenic cooperation model in vivo, multiple independent experiments","pmids":["32156729"],"is_preprint":false},{"year":2023,"finding":"Somatic mutations at the menin-MLL1 interface (revumenib-menin interface) confer clinical resistance to menin inhibition. These mutations attenuate drug-target binding via structural perturbations that impact small-molecule binding but not the natural MLL1 interaction, and prevent inhibitor-induced eviction of menin and MLL1 from chromatin.","method":"Clinical resistance mutation sequencing, xenograft models, base-editor screen, structural perturbation analysis, chromatin immunoprecipitation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clinical genomics plus xenograft validation plus unbiased base-editor screen plus ChIP; multiple independent and orthogonal methods","pmids":["36922589"],"is_preprint":false},{"year":2023,"finding":"MEN1 protein is degraded via the neddylation pathway and CUL4B-DCAF7-mediated ubiquitination. DCAF7 binds menin and catalyzes its ubiquitination, leading to proteasomal degradation. Suppression of neddylation (MLN4924) or DCAF7 knockdown induces MEN1 accumulation, and the oncogenic effects of DCAF7 loss are counteracted by simultaneous MEN1 knockdown.","method":"Co-immunoprecipitation, ubiquitination assay, RNAi knockdown, neddylation inhibitor (MLN4924), in vitro and in vivo rescue experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vitro ubiquitination assay, genetic rescue in vivo, multiple orthogonal methods in single study","pmids":["36939378"],"is_preprint":false},{"year":2024,"finding":"MEN1 knockout redistributes MLL1 chromatin occupancy, increasing H3K4me3 at repetitive genomic regions, activating double-stranded RNA expression, and increasing immune cell infiltration. Pharmacological inhibition of the menin-MLL interaction reduces tumor growth in a CD8+ T cell-dependent manner, revealing a tumor microenvironment-dependent function of MEN1.","method":"In vivo CRISPR-Cas9 screen in xenograft vs. 2D culture, ChIP-seq (H3K4me3), dsRNA expression analysis, immune cell profiling, pharmacologic menin-MLL inhibition in immunocompetent and immunodeficient mice, CD8+ T cell depletion","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo CRISPR screen, ChIP-seq, mechanistic immune profiling, and pharmacologic validation with cell-depletion controls — multiple orthogonal methods","pmids":["39227744"],"is_preprint":false},{"year":2011,"finding":"MEN1, encoding menin, is a component of a histone methyltransferase complex; 44% of pancreatic neuroendocrine tumors carry somatic inactivating mutations in MEN1, establishing menin as a chromatin remodeling factor whose loss contributes to PanNET tumorigenesis.","method":"Exome sequencing of 68 PanNETs, mutation screening","journal":"Science (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — large-scale somatic mutation survey identifying MEN1 as chromatin remodeler component, single method (sequencing), but highly replicated across many tumors","pmids":["21252315"],"is_preprint":false},{"year":2020,"finding":"MEN1 deficiency in a KrasG12D lung cancer mouse model leads to accumulation of DNA damage and antagonizes oncogenic Kras-induced senescence and the epithelial-to-mesenchymal transition, resulting in neuroendocrine differentiation of lung cancer.","method":"ATII-specific KrasG12D/Men1-/- genetically engineered mouse model, DNA damage markers, senescence assays, EMT marker analysis, NE differentiation markers","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO model with multiple molecular readouts (DNA damage, senescence, EMT, NE markers), single lab","pmids":["32081882"],"is_preprint":false},{"year":2007,"finding":"In Men1(+/-)Rb(+/-) compound mice, loss of the remaining wild-type Men1 and Rb alleles is mutually exclusive in all tumors, indicating that Men1 and Rb act in the same pathway. Down-regulation of Men1 targets p18 and p27 and increased phospho-Rb were observed in Men1-deficient pheochromocytomas. RNAi knockdown of Men1 increased apoptosis in Rb-deficient medullary thyroid carcinoma cells, revealing cell lineage-specific interactions.","method":"Compound mutant mouse model, LOH analysis, p18/p27 expression analysis, phospho-Rb western blot, RNAi knockdown in cell lines","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo epistasis with molecular pathway validation (p18, p27, phospho-Rb), single lab","pmids":["17893233"],"is_preprint":false},{"year":2022,"finding":"GFAP-directed Men1 inactivation in glial cells induces neuroendocrine differentiation and tumorigenesis (pancreatic NETs, prolactinomas). Men1 deletion causes loss of glial progenitor markers and gain of neuroendocrine genes. Co-deletion of Kif3a (Hedgehog mediator) attenuates neuroendocrine hyperplasia, implicating Hedgehog signaling downstream of Men1 in glial-to-neuroendocrine reprogramming.","method":"Conditional Men1 KO (GFAP-Cre), Cre lineage tracing (tdTomato), gene expression analysis, double KO (Kif3a/Men1 and Sox10/Men1)","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with lineage tracing and genetic epistasis, single lab","pmids":["35835391"],"is_preprint":false},{"year":2022,"finding":"Menin promotes ferroptosis in pancreatic neuroendocrine tumor cells by inhibiting the mTOR-SCD1 axis. MEN1 overexpression suppresses mTOR signaling and reduces SCD1 expression; oleic acid (an SCD1 metabolite) rescues lipid peroxidation caused by MEN1 overexpression. MEN1-overexpressing cells are more sensitive to the mTOR inhibitor everolimus.","method":"Targeted metabolomics, MEN1 overexpression/knockdown in pNET cells, mTOR pathway analysis, SCD1 expression assay, ferroptosis assays, lipid peroxidation measurement, everolimus sensitivity assay","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple molecular assays linking MEN1 to mTOR-SCD1-ferroptosis pathway, single lab","pmids":["36604142"],"is_preprint":false},{"year":2017,"finding":"MEN1/Menin suppresses the PI3K/Akt/mTOR pathway in bovine mammary epithelial cells; menin overexpression significantly suppresses mTOR pathway factors and milk protein κ-casein, while MEN1 knockdown increases them. Menin also negatively modulates responses to prolactin and insulin upstream of mTOR.","method":"MEN1 overexpression and knockdown in bovine mammary epithelial cells and tissues, mTOR pathway western blotting, milk protein (κ-casein) expression analysis","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell type, gain/loss-of-function with pathway markers but no rescue experiment or structural validation","pmids":["28710500"],"is_preprint":false},{"year":2020,"finding":"A 596 bp deletion in the 5' UTR of MEN1 including the core promoter causes significant reductions (37-fold in HEK293, 16-fold in BON-1) in promoter-driven luciferase expression, and 84% and 88% reductions in MEN1 mRNA and menin protein, respectively, in patient-derived lymphoblastoid cells, establishing a regulatory role for the MEN1 5' UTR in menin expression.","method":"Luciferase reporter assay, qRT-PCR, Western blotting in patient-derived EBV-transformed lymphoblastoid cells","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay complemented by endogenous mRNA and protein measurement in patient cells, single lab, two orthogonal methods","pmids":["32780883"],"is_preprint":false}],"current_model":"Menin is a predominantly nuclear scaffold protein (with C-terminal NLS sequences) that functions as a tumor suppressor by: (1) forming part of MLL1/MLL2 histone H3K4 methyltransferase complexes to regulate chromatin and transcription; (2) recruiting PRMT5 to gene promoters (e.g., Gas1) to impose repressive H4R3m2s marks and suppress Hedgehog signaling; (3) repressing JunD-mediated transcription; (4) maintaining CDK inhibitor expression (p18Ink4c, p27Kip1) to restrain G1-to-S cell cycle progression via CDK4 and Rb; (5) suppressing the mTOR pathway to promote ferroptosis; (6) regulating exocrine pancreas homeostasis partly through restraint of JunD target genes; and (7) maintaining chromatin occupancy patterns such that its loss redistributes MLL1 to repetitive elements and activates dsRNA/immune responses; menin protein stability is controlled post-translationally by CUL4B-DCAF7-mediated ubiquitination and neddylation-dependent proteasomal degradation."},"narrative":{"mechanistic_narrative":"Menin, encoded by MEN1, is a predominantly nuclear scaffold protein that acts as a tumor suppressor by coordinating chromatin-based transcriptional control with cell cycle restraint, and its inactivation drives neuroendocrine tumorigenesis [PMID:9465067, PMID:21252315]. It restrains the G0/G1-to-S transition by maintaining expression of the CDK inhibitors p18(Ink4c) and p27(Kip1); loss of menin elevates CDK2 activity and accelerates S-phase entry, and complementation with wild-type menin reverses this [PMID:16740708]. Genetic epistasis establishes that p18(Ink4c) and menin act in the same pathway to suppress neuroendocrine and lung tumors through control of Rb phosphorylation, with CDK4 — not CDK2 — being the kinase required for MEN1-dependent pituitary and islet tumorigenesis [PMID:17145768, PMID:17409423, PMID:24531709]; menin and Rb likewise operate in a shared, lineage-specific pathway [PMID:17893233]. Menin enforces transcriptional programs through chromatin: it recruits PRMT5 to target promoters such as Gas1 to deposit repressive H4R3me2s marks and suppress Hedgehog signaling, and disease-associated menin mutants fail to bind PRMT5 or impose this mark [PMID:23580576, PMID:35835391]; it also represses JunD-mediated transcription, a function conserved to zebrafish [PMID:10818209]. Within the MLL1 histone H3K4 methyltransferase complex, menin maintains normal chromatin occupancy, and its loss redistributes MLL1 to repetitive elements, raising H3K4me3 there, inducing double-stranded RNA expression and immune infiltration, such that menin-MLL inhibition restrains tumors in a CD8+ T cell-dependent manner [PMID:39227744]. Menin loss also restrains differentiated-cell plasticity, permitting transdifferentiation of pancreatic alpha cells into insulinoma cells and reprogramming of glial cells toward neuroendocrine fates [PMID:20138042, PMID:35835391]. Menin protein abundance is set post-translationally by CUL4B-DCAF7-mediated, neddylation-dependent ubiquitination and proteasomal degradation, and is stabilized in response to tissue injury [PMID:32156729, PMID:36939378]. Inactivating somatic MEN1 mutations and a 5'UTR/core-promoter deletion that collapses menin expression underlie pancreatic neuroendocrine and MEN1-related tumors [PMID:21252315, PMID:32780883], and clinical resistance to menin inhibitors arises from mutations at the menin-MLL1 drug interface that block inhibitor-induced eviction of menin and MLL1 from chromatin without disrupting the native MLL1 interaction [PMID:36922589].","teleology":[{"year":1998,"claim":"Established where menin acts in the cell, defining it as a nuclear protein with discrete C-terminal localization signals — a prerequisite for any chromatin/transcriptional model.","evidence":"Immunofluorescence, subcellular fractionation, and GFP deletion mapping","pmids":["9465067"],"confidence":"High","gaps":["Does not define molecular activity or binding partners","NLS mapping does not address cytoplasmic functions later reported"]},{"year":2000,"claim":"Identified a conserved transcriptional output for menin by showing it binds JunD and represses JunD-driven transcription, the first specific mechanistic activity assigned.","evidence":"Protein binding and reporter assays in a zebrafish ortholog system","pmids":["10818209"],"confidence":"Medium","gaps":["Ortholog/reporter system, not endogenous human loci","Does not establish how JunD repression links to tumor suppression"]},{"year":2006,"claim":"Connected menin loss to cell cycle deregulation, showing it maintains CDK inhibitors p18/p27 to restrain S-phase entry, providing a proliferative mechanism for tumor suppression.","evidence":"Conditional Men1 knockout in MEFs and islets with cell cycle, CDK2, and rescue analyses","pmids":["16740708"],"confidence":"High","gaps":["Does not resolve which downstream CDK is rate-limiting in vivo","Mechanism by which menin maintains p18/p27 transcription not defined here"]},{"year":2006,"claim":"Pinpointed p18(Ink4c) as the genetically relevant collaborator with menin in the same Rb pathway, distinguishing it from p27 in neuroendocrine tumor suppression.","evidence":"Double-mutant mouse epistasis, Rb phosphorylation, and LOH analysis","pmids":["17145768"],"confidence":"High","gaps":["Tissue specificity of p18 vs p27 contribution not fully explained","Does not identify the CDK enforcing the Rb phenotype"]},{"year":2007,"claim":"Extended the menin-p18 collaboration to lung stem cell expansion and NSCLC, showing the pathway operates beyond endocrine tissues.","evidence":"p18(-/-);Men1(+/-) mouse lung tumor model with stem cell quantification and Rb phosphorylation","pmids":["17409423"],"confidence":"High","gaps":["Does not define menin's molecular role in stem cell compartment","Relative contribution of CDK2 vs CDK4/6 sites not resolved"]},{"year":2007,"claim":"Placed Men1 and Rb in the same pathway via mutually exclusive allele loss and revealed lineage-specific consequences of menin loss.","evidence":"Men1;Rb compound mouse model, LOH, phospho-Rb, and RNAi in tumor cells","pmids":["17893233"],"confidence":"Medium","gaps":["Mechanism of cell-lineage-specific apoptosis on Men1 knockdown unclear","Single lab"]},{"year":2010,"claim":"Demonstrated that menin restrains differentiated cell plasticity, with its loss permitting alpha-to-beta cell transdifferentiation into insulinoma — a fate-control rather than purely proliferative role.","evidence":"Alpha cell-specific Men1 knockout with genetic lineage tracing","pmids":["20138042"],"confidence":"High","gaps":["Molecular mediators of the transdifferentiation not identified","Does not link fate change to specific menin chromatin targets"]},{"year":2011,"claim":"Established the clinical and biological weight of MEN1 loss by showing somatic inactivating mutations in ~44% of PanNETs and framing menin as a chromatin/HMT-complex component.","evidence":"Exome sequencing of 68 pancreatic neuroendocrine tumors","pmids":["21252315"],"confidence":"Medium","gaps":["Sequencing alone does not demonstrate mechanism","Does not show which chromatin function is lost in tumors"]},{"year":2013,"claim":"Defined a direct epigenetic-repressive mechanism: menin recruits PRMT5 to deposit H4R3me2s and silence Hedgehog target Gas1, with disease mutants failing this — linking chromatin marks to a tumorigenic pathway.","evidence":"Reciprocal Co-IP, ChIP, reporter assays, mutant binding, and pharmacologic Hedgehog inhibition in MEN1 tumors","pmids":["23580576"],"confidence":"High","gaps":["Genome-wide extent of PRMT5 recruitment not mapped","Relationship between PRMT5 and MLL1 complexes not resolved"]},{"year":2014,"claim":"Resolved which CDK is rate-limiting, showing CDK4 (not CDK2) is required for MEN1-dependent pituitary and islet tumorigenesis, refining therapeutic targeting downstream of menin.","evidence":"Men1;Cdk4 and Men1;Cdk2 double-mutant mice plus CDK knockdown in insulinoma cells with phospho-RB readout","pmids":["24531709"],"confidence":"High","gaps":["Does not reconcile with earlier CDK2 activity findings across tissues","Mechanism connecting menin loss to CDK4 activation not defined"]},{"year":2016,"claim":"Proposed a DNA-methylation arm of menin tumor suppression, where loss activates DNMT1 via Rbbp5, causing hypermethylation that silences Sox genes and activates Wnt/beta-catenin.","evidence":"Genome-wide methylation analysis in MEN1 tumors, Men1 KO mice and MEFs, DNMT1 activity assays","pmids":["26871472"],"confidence":"Medium","gaps":["Single lab; mechanism of Rbbp5-DNMT1 activation needs orthogonal validation","Causal link between hypermethylation and Wnt activation not fully established"]},{"year":2020,"claim":"Showed menin governs exocrine pancreas injury response and regeneration partly via JunD target restraint, and cooperates with mutant Kras in oncogenesis, with menin protein stabilized upon insult.","evidence":"Conditional Men1 KO with caerulein pancreatitis, KrasG12D compound model, and protein stability assay","pmids":["32156729"],"confidence":"High","gaps":["How injury stabilizes menin protein not mechanistically defined","Direct JunD target set in exocrine pancreas not enumerated"]},{"year":2020,"claim":"Revealed that menin loss antagonizes Kras-induced senescence and EMT and drives neuroendocrine differentiation of lung cancer, with DNA damage accumulation.","evidence":"ATII KrasG12D/Men1-/- mouse model with DNA damage, senescence, EMT and NE marker analysis","pmids":["32081882"],"confidence":"Medium","gaps":["Molecular mechanism linking menin loss to NE reprogramming not defined","Single lab"]},{"year":2020,"claim":"Demonstrated that the MEN1 5'UTR/core promoter is required for menin expression, identifying a regulatory cause of menin loss beyond coding mutations.","evidence":"Luciferase reporter, qRT-PCR, and Western blotting in patient-derived lymphoblastoid cells","pmids":["32780883"],"confidence":"Medium","gaps":["Transcription factors acting at this promoter not identified","Single patient-derived deletion characterized"]},{"year":2022,"claim":"Identified a metabolic tumor-suppressive function in which menin promotes ferroptosis by inhibiting the mTOR-SCD1 axis in pNET cells.","evidence":"Metabolomics, MEN1 gain/loss, mTOR/SCD1 readouts, lipid peroxidation, and oleic acid/everolimus rescue","pmids":["36604142"],"confidence":"Medium","gaps":["How nuclear menin suppresses mTOR mechanistically unclear","Single lab"]},{"year":2022,"claim":"Showed menin loss reprograms glial cells toward neuroendocrine fates via downstream Hedgehog signaling, linking fate control to the PRMT5/Hedgehog axis.","evidence":"GFAP-Cre Men1 KO with lineage tracing and Kif3a/Sox10 genetic epistasis","pmids":["35835391"],"confidence":"Medium","gaps":["Direct chromatin targets driving reprogramming not mapped","Single lab"]},{"year":2023,"claim":"Defined the post-translational control of menin abundance, identifying CUL4B-DCAF7 as the E3 machinery and neddylation as required for its degradation.","evidence":"Reciprocal Co-IP, in vitro ubiquitination, RNAi, MLN4924, and in vivo genetic rescue","pmids":["36939378"],"confidence":"High","gaps":["Signals triggering DCAF7-mediated degradation not defined","Site(s) of menin ubiquitination not mapped"]},{"year":2023,"claim":"Explained clinical menin-inhibitor resistance, showing mutations at the menin-MLL1 drug interface block inhibitor-induced chromatin eviction without disrupting the native interaction.","evidence":"Clinical resistance sequencing, xenografts, base-editor screen, structural and ChIP analysis","pmids":["36922589"],"confidence":"High","gaps":["Strategies to overcome interface resistance not established","Does not address resistance arising outside the interface"]},{"year":2024,"claim":"Uncovered a tumor microenvironment-dependent function: menin loss redistributes MLL1, activates dsRNA/immune responses, and renders tumors sensitive to menin-MLL inhibition via CD8+ T cells.","evidence":"In vivo CRISPR screen, H3K4me3 ChIP-seq, dsRNA and immune profiling, and immune-competent vs depleted mouse models","pmids":["39227744"],"confidence":"High","gaps":["Mechanism restraining MLL1 redistribution by menin not detailed","Generalizability across tumor types not established"]},{"year":null,"claim":"How menin's distinct nuclear activities — MLL1 H3K4 methylation, PRMT5 recruitment, JunD repression, and DNMT1 regulation — are integrated on chromatin, and how these connect to cytoplasmic mTOR/ferroptosis control, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking menin's repressive and activating chromatin functions","Mechanism by which a nuclear scaffold modulates mTOR signaling unclear","Cell-type determinants of menin's opposing roles not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,5,12]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[5,11]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[5,12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[0,5]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[5,12,13]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,5,8]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,3,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,13,19]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[11]}],"complexes":["MLL1 H3K4 methyltransferase complex","CUL4B-DCAF7 E3 ubiquitin ligase complex"],"partners":["MLL1","PRMT5","JUND","DCAF7","CUL4B","RBBP5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00255","full_name":"Menin","aliases":[],"length_aa":610,"mass_kda":67.5,"function":"Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O00255/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MEN1","classification":"Not Classified","n_dependent_lines":394,"n_total_lines":1208,"dependency_fraction":0.326158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"NUMA1","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2},{"gene":"TOP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/MEN1","total_profiled":1310},"omim":[{"mim_id":"617686","title":"PITUITARY ADENOMA 3, MULTIPLE TYPES; PITA3","url":"https://www.omim.org/entry/617686"},{"mim_id":"617343","title":"HYPERPARATHYROIDISM 4; HRPT4","url":"https://www.omim.org/entry/617343"},{"mim_id":"615555","title":"HYPERPROLACTINEMIA; HPRL","url":"https://www.omim.org/entry/615555"},{"mim_id":"613733","title":"MENIN 1; MEN1","url":"https://www.omim.org/entry/613733"},{"mim_id":"610755","title":"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV; MEN4","url":"https://www.omim.org/entry/610755"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MEN1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O00255","domains":[{"cath_id":"-","chopping":"2-274","consensus_level":"medium","plddt":94.8136,"start":2,"end":274}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00255","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00255-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00255-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MEN1","jax_strain_url":"https://www.jax.org/strain/search?query=MEN1"},"sequence":{"accession":"O00255","fasta_url":"https://rest.uniprot.org/uniprotkb/O00255.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00255/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00255"}},"corpus_meta":[{"pmid":"21252315","id":"PMC_21252315","title":"DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21252315","citation_count":1396,"is_preprint":false},{"pmid":"22723327","id":"PMC_22723327","title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22723327","citation_count":959,"is_preprint":false},{"pmid":"9215690","id":"PMC_9215690","title":"Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9215690","citation_count":518,"is_preprint":false},{"pmid":"17879353","id":"PMC_17879353","title":"Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene.","date":"2008","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17879353","citation_count":456,"is_preprint":false},{"pmid":"9465067","id":"PMC_9465067","title":"Menin, the product of the MEN1 gene, is a nuclear protein.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9465067","citation_count":357,"is_preprint":false},{"pmid":"9241276","id":"PMC_9241276","title":"Somatic mutation of the MEN1 gene in parathyroid tumours.","date":"1997","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9241276","citation_count":347,"is_preprint":false},{"pmid":"23933118","id":"PMC_23933118","title":"Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23933118","citation_count":267,"is_preprint":false},{"pmid":"9361035","id":"PMC_9361035","title":"Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9361035","citation_count":198,"is_preprint":false},{"pmid":"36922589","id":"PMC_36922589","title":"MEN1 mutations mediate clinical resistance to menin inhibition.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/36922589","citation_count":197,"is_preprint":false},{"pmid":"12917331","id":"PMC_12917331","title":"Of mice and MEN1: Insulinomas in a conditional mouse knockout.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12917331","citation_count":195,"is_preprint":false},{"pmid":"30315258","id":"PMC_30315258","title":"ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30315258","citation_count":178,"is_preprint":false},{"pmid":"20833329","id":"PMC_20833329","title":"Multiple endocrine neoplasia type 1 (MEN1).","date":"2010","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20833329","citation_count":165,"is_preprint":false},{"pmid":"22575867","id":"PMC_22575867","title":"Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.","date":"2012","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/22575867","citation_count":142,"is_preprint":false},{"pmid":"31263451","id":"PMC_31263451","title":"Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31263451","citation_count":140,"is_preprint":false},{"pmid":"20566584","id":"PMC_20566584","title":"MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases.","date":"2010","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20566584","citation_count":131,"is_preprint":false},{"pmid":"9824159","id":"PMC_9824159","title":"Characterization of the mouse Men1 gene and its expression during development.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9824159","citation_count":118,"is_preprint":false},{"pmid":"15060136","id":"PMC_15060136","title":"Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15060136","citation_count":114,"is_preprint":false},{"pmid":"19309299","id":"PMC_19309299","title":"Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity.","date":"2009","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19309299","citation_count":109,"is_preprint":false},{"pmid":"27842554","id":"PMC_27842554","title":"MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients.","date":"2016","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27842554","citation_count":108,"is_preprint":false},{"pmid":"20138042","id":"PMC_20138042","title":"Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development.","date":"2010","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20138042","citation_count":105,"is_preprint":false},{"pmid":"15153434","id":"PMC_15153434","title":"Molecular pathology of the MEN1 gene.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15153434","citation_count":102,"is_preprint":false},{"pmid":"26767918","id":"PMC_26767918","title":"Multiple endocrine neoplasia type 1 (MEN1): An update of 208 new germline variants reported in the last nine years.","date":"2015","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26767918","citation_count":102,"is_preprint":false},{"pmid":"16740708","id":"PMC_16740708","title":"Mutation of tumor suppressor gene Men1 acutely enhances proliferation of pancreatic islet cells.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16740708","citation_count":95,"is_preprint":false},{"pmid":"23580576","id":"PMC_23580576","title":"Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23580576","citation_count":88,"is_preprint":false},{"pmid":"9935177","id":"PMC_9935177","title":"MEN1 gene mutation analysis of sporadic adrenocortical lesions.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9935177","citation_count":77,"is_preprint":false},{"pmid":"19904212","id":"PMC_19904212","title":"Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors.","date":"2009","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19904212","citation_count":76,"is_preprint":false},{"pmid":"9888389","id":"PMC_9888389","title":"Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases.","date":"1999","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/9888389","citation_count":76,"is_preprint":false},{"pmid":"9920087","id":"PMC_9920087","title":"MEN1 gene analysis in sporadic adrenocortical neoplasms.","date":"1999","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9920087","citation_count":75,"is_preprint":false},{"pmid":"28899949","id":"PMC_28899949","title":"The future: genetics advances in MEN1 therapeutic approaches and management strategies.","date":"2017","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28899949","citation_count":66,"is_preprint":false},{"pmid":"17890894","id":"PMC_17890894","title":"Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance.","date":"2007","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17890894","citation_count":62,"is_preprint":false},{"pmid":"10341092","id":"PMC_10341092","title":"Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene.","date":"1999","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/10341092","citation_count":58,"is_preprint":false},{"pmid":"12755956","id":"PMC_12755956","title":"Functional studies of the MEN1 gene.","date":"2003","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12755956","citation_count":57,"is_preprint":false},{"pmid":"30339208","id":"PMC_30339208","title":"UMD-MEN1 Database: An Overview of the 370 MEN1 Variants Present in 1676 Patients From the French Population.","date":"2019","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30339208","citation_count":55,"is_preprint":false},{"pmid":"25592387","id":"PMC_25592387","title":"MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics.","date":"2015","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25592387","citation_count":54,"is_preprint":false},{"pmid":"29449689","id":"PMC_29449689","title":"Current and emerging therapies for PNETs in patients with or without MEN1.","date":"2018","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29449689","citation_count":51,"is_preprint":false},{"pmid":"28130400","id":"PMC_28130400","title":"Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28130400","citation_count":51,"is_preprint":false},{"pmid":"10389976","id":"PMC_10389976","title":"Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10389976","citation_count":50,"is_preprint":false},{"pmid":"10366412","id":"PMC_10366412","title":"Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis.","date":"1999","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10366412","citation_count":48,"is_preprint":false},{"pmid":"9820618","id":"PMC_9820618","title":"MEN1 gene mutations in 12 MEN1 families and their associated tumors.","date":"1998","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9820618","citation_count":47,"is_preprint":false},{"pmid":"17145768","id":"PMC_17145768","title":"p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17145768","citation_count":47,"is_preprint":false},{"pmid":"10738303","id":"PMC_10738303","title":"MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma.","date":"2000","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10738303","citation_count":45,"is_preprint":false},{"pmid":"10993647","id":"PMC_10993647","title":"Identification of MEN1 gene mutations in families with MEN 1 and related disorders.","date":"2000","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10993647","citation_count":45,"is_preprint":false},{"pmid":"28811299","id":"PMC_28811299","title":"Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1.","date":"2017","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28811299","citation_count":43,"is_preprint":false},{"pmid":"22577108","id":"PMC_22577108","title":"MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.","date":"2012","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22577108","citation_count":42,"is_preprint":false},{"pmid":"30254610","id":"PMC_30254610","title":"The Importance of an Early and Accurate MEN1 Diagnosis.","date":"2018","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30254610","citation_count":41,"is_preprint":false},{"pmid":"11223240","id":"PMC_11223240","title":"Characterization of a MEN1 ortholog from Drosophila melanogaster.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11223240","citation_count":41,"is_preprint":false},{"pmid":"17409423","id":"PMC_17409423","title":"p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17409423","citation_count":38,"is_preprint":false},{"pmid":"9893060","id":"PMC_9893060","title":"Studies of the murine homolog of the multiple endocrine neoplasia type 1 (MEN1) gene, men1.","date":"1999","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/9893060","citation_count":38,"is_preprint":false},{"pmid":"40523372","id":"PMC_40523372","title":"Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice.","date":"2025","source":"The lancet. Diabetes & endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/40523372","citation_count":37,"is_preprint":false},{"pmid":"19068082","id":"PMC_19068082","title":"MEN1 gene and its mutations: basic and clinical implications.","date":"2009","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19068082","citation_count":37,"is_preprint":false},{"pmid":"32081882","id":"PMC_32081882","title":"MEN1 deficiency leads to neuroendocrine differentiation of lung cancer and disrupts the DNA damage response.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32081882","citation_count":37,"is_preprint":false},{"pmid":"36939378","id":"PMC_36939378","title":"MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36939378","citation_count":36,"is_preprint":false},{"pmid":"10664520","id":"PMC_10664520","title":"MEN1 gene mutation analysis in Italian patients with multiple endocrine neoplasia type 1.","date":"2000","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10664520","citation_count":36,"is_preprint":false},{"pmid":"33312161","id":"PMC_33312161","title":"Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33312161","citation_count":35,"is_preprint":false},{"pmid":"9681840","id":"PMC_9681840","title":"Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene.","date":"1998","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9681840","citation_count":34,"is_preprint":false},{"pmid":"9681842","id":"PMC_9681842","title":"Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1).","date":"1998","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9681842","citation_count":34,"is_preprint":false},{"pmid":"10818209","id":"PMC_10818209","title":"Isolation, characterization, expression and functional analysis of the zebrafish ortholog of MEN1.","date":"2000","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/10818209","citation_count":33,"is_preprint":false},{"pmid":"19407509","id":"PMC_19407509","title":"The MEN1 gene and pituitary tumours.","date":"2009","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/19407509","citation_count":32,"is_preprint":false},{"pmid":"17893233","id":"PMC_17893233","title":"Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17893233","citation_count":32,"is_preprint":false},{"pmid":"27038812","id":"PMC_27038812","title":"Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas.","date":"2016","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/27038812","citation_count":32,"is_preprint":false},{"pmid":"22584706","id":"PMC_22584706","title":"Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation.","date":"2012","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/22584706","citation_count":32,"is_preprint":false},{"pmid":"24531709","id":"PMC_24531709","title":"MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24531709","citation_count":31,"is_preprint":false},{"pmid":"26860771","id":"PMC_26860771","title":"Deletion of Men1 and somatostatin induces hypergastrinemia and gastric carcinoids.","date":"2016","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/26860771","citation_count":30,"is_preprint":false},{"pmid":"29903750","id":"PMC_29903750","title":"DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.","date":"2018","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29903750","citation_count":30,"is_preprint":false},{"pmid":"32937789","id":"PMC_32937789","title":"Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32937789","citation_count":29,"is_preprint":false},{"pmid":"11966738","id":"PMC_11966738","title":"Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism.","date":"2002","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11966738","citation_count":29,"is_preprint":false},{"pmid":"10594843","id":"PMC_10594843","title":"MEN1 gene mutations in sporadic neuroendocrine tumors of foregut derivation.","date":"1999","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/10594843","citation_count":28,"is_preprint":false},{"pmid":"33905872","id":"PMC_33905872","title":"Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs).","date":"2021","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/33905872","citation_count":27,"is_preprint":false},{"pmid":"10529376","id":"PMC_10529376","title":"Characterization of the MEN1 ortholog in zebrafish.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10529376","citation_count":26,"is_preprint":false},{"pmid":"17613551","id":"PMC_17613551","title":"Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17613551","citation_count":26,"is_preprint":false},{"pmid":"32311048","id":"PMC_32311048","title":"Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly.","date":"2020","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32311048","citation_count":25,"is_preprint":false},{"pmid":"31489630","id":"PMC_31489630","title":"A somatic mutation in MEN1 gene detected in periventricular nodular heterotopia tissue obtained from depth electrodes.","date":"2019","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/31489630","citation_count":25,"is_preprint":false},{"pmid":"30721134","id":"PMC_30721134","title":"Adrenocortical carcinoma in patients with MEN1: a kindred report and review of the literature.","date":"2019","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/30721134","citation_count":24,"is_preprint":false},{"pmid":"28469779","id":"PMC_28469779","title":"Analysis of differentially expressed microRNAs in MEN1 parathyroid adenomas.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28469779","citation_count":24,"is_preprint":false},{"pmid":"31044390","id":"PMC_31044390","title":"True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndrome.","date":"2019","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/31044390","citation_count":23,"is_preprint":false},{"pmid":"26871472","id":"PMC_26871472","title":"Loss of MEN1 activates DNMT1 implicating DNA hypermethylation as a driver of MEN1 tumorigenesis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26871472","citation_count":23,"is_preprint":false},{"pmid":"11027505","id":"PMC_11027505","title":"Heterogeneity at the 5'-end of MEN1 transcripts.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11027505","citation_count":23,"is_preprint":false},{"pmid":"19474519","id":"PMC_19474519","title":"Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.","date":"2009","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19474519","citation_count":23,"is_preprint":false},{"pmid":"22915754","id":"PMC_22915754","title":"MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22915754","citation_count":23,"is_preprint":false},{"pmid":"23778871","id":"PMC_23778871","title":"A MEN1 syndrome with a paraganglioma.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/23778871","citation_count":22,"is_preprint":false},{"pmid":"22825745","id":"PMC_22825745","title":"Alterations of MEN1 and E-cadherin/β-catenin complex in sporadic pulmonary carcinoids.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22825745","citation_count":21,"is_preprint":false},{"pmid":"39227744","id":"PMC_39227744","title":"In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions.","date":"2024","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39227744","citation_count":20,"is_preprint":false},{"pmid":"11740047","id":"PMC_11740047","title":"The MEN1 gene and associated diseases: an update.","date":"2001","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11740047","citation_count":20,"is_preprint":false},{"pmid":"31658439","id":"PMC_31658439","title":"Whole genome sequencing of apparently mutation-negative MEN1 patients.","date":"2020","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31658439","citation_count":20,"is_preprint":false},{"pmid":"28710500","id":"PMC_28710500","title":"MEN1/Menin regulates milk protein synthesis through mTOR signaling in mammary epithelial cells.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28710500","citation_count":20,"is_preprint":false},{"pmid":"29615472","id":"PMC_29615472","title":"Epigenetic regulation in the tumorigenesis of MEN1-associated endocrine cell types.","date":"2018","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29615472","citation_count":19,"is_preprint":false},{"pmid":"29927501","id":"PMC_29927501","title":"Children with MEN1 gene mutations may present first (and at a young age) with Cushing disease.","date":"2018","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29927501","citation_count":19,"is_preprint":false},{"pmid":"28597079","id":"PMC_28597079","title":"MEN1 mutations and potentially MEN1-targeting miRNAs are responsible for menin deficiency in sporadic and MEN1 syndrome-associated primary hyperparathyroidism.","date":"2017","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28597079","citation_count":19,"is_preprint":false},{"pmid":"25625803","id":"PMC_25625803","title":"MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25625803","citation_count":18,"is_preprint":false},{"pmid":"28420716","id":"PMC_28420716","title":"A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control.","date":"2017","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/28420716","citation_count":18,"is_preprint":false},{"pmid":"35835391","id":"PMC_35835391","title":"GFAP-directed Inactivation of Men1 Exploits Glial Cell Plasticity in Favor of Neuroendocrine Reprogramming.","date":"2022","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35835391","citation_count":17,"is_preprint":false},{"pmid":"31557724","id":"PMC_31557724","title":"MEN1-associated primary hyperparathyroidism in the Spanish Registry: clinical characterictics and surgical outcomes.","date":"2019","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/31557724","citation_count":17,"is_preprint":false},{"pmid":"17953629","id":"PMC_17953629","title":"MEN1 gene mutations in Hungarian patients with multiple endocrine neoplasia type 1.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17953629","citation_count":17,"is_preprint":false},{"pmid":"15754732","id":"PMC_15754732","title":"Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics.","date":"2004","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15754732","citation_count":17,"is_preprint":false},{"pmid":"28743793","id":"PMC_28743793","title":"Animal models of MEN1.","date":"2017","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28743793","citation_count":16,"is_preprint":false},{"pmid":"22542456","id":"PMC_22542456","title":"MEN1 and pituitary adenomas.","date":"2012","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/22542456","citation_count":16,"is_preprint":false},{"pmid":"32780883","id":"PMC_32780883","title":"Multiple Endocrine Neoplasia Type 1 (MEN1) 5'UTR Deletion, in MEN1 Family, Decreases Menin Expression.","date":"2020","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/32780883","citation_count":16,"is_preprint":false},{"pmid":"32156729","id":"PMC_32156729","title":"Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32156729","citation_count":16,"is_preprint":false},{"pmid":"23435440","id":"PMC_23435440","title":"Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1).","date":"2013","source":"Minerva endocrinologica","url":"https://pubmed.ncbi.nlm.nih.gov/23435440","citation_count":15,"is_preprint":false},{"pmid":"36604142","id":"PMC_36604142","title":"MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors.","date":"2022","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/36604142","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52066,"output_tokens":5362,"usd":0.118314,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13874,"output_tokens":5738,"usd":0.10641,"stage2_stop_reason":"end_turn"},"total_usd":0.224724,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Menin is located primarily in the nucleus, with at least two independent nuclear localization signals (NLS) both located in the C-terminal fourth of the protein, as determined by immunofluorescence, subcellular fractionation Western blotting, and GFP-tagging of deletion constructs.\",\n      \"method\": \"Immunofluorescence, Western blotting of subcellular fractions, epitope-tagged GFP deletion constructs\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (immunofluorescence, fractionation, GFP deletion mapping) in a single focused study, replicated by subsequent studies\",\n      \"pmids\": [\"9465067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Zebrafish menin binds both human and mouse JunD and represses JunD-induced transcription, demonstrating that the JunD-binding and transcriptional repression function of menin is evolutionarily conserved.\",\n      \"method\": \"Protein binding assay, transcriptional reporter assay in zebrafish\",\n      \"journal\": \"Mammalian genome : official journal of the International Mammalian Genome Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional binding and reporter assay in an ortholog system, single lab but two methods\",\n      \"pmids\": [\"10818209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Men1 excision in mouse embryonic fibroblasts accelerates G0/G1 to S phase entry, accompanied by increased CDK2 activity and decreased expression of CDK inhibitors p18(Ink4c) and p27(Kip1). Complementation with wild-type menin represses S-phase entry. In vivo, Men1 excision in pancreatic islets increases proliferation within 7 days.\",\n      \"method\": \"Conditional Men1 knockout in MEFs (Cre-lox), cell cycle analysis, CDK2 kinase assay, in vivo tamoxifen-inducible Men1 deletion in pancreatic islets with BrdU labeling\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro and in vivo loss-of-function with specific molecular readouts (CDK2 activity, p18/p27 expression, cell cycle), complementation rescue performed\",\n      \"pmids\": [\"16740708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Genetic epistasis in mice shows that p18(Ink4c), but not p27(Kip1), functionally collaborates with Men1 to suppress neuroendocrine organ tumors. p18(-/-);Men1(+/-) mice develop tumors at accelerated rates with increased Rb phosphorylation at both CDK2 and CDK4/6 sites, and the remaining wild-type Men1 allele is often retained in p18-null compound tumors, indicating functional redundancy between p18 and Men1 in the same pathway.\",\n      \"method\": \"Double-mutant mouse epistasis, tumor incidence analysis, Rb phosphorylation western blotting, LOH analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo with molecular pathway validation (Rb phosphorylation), replicated concept in lung tumors (PMID 17409423)\",\n      \"pmids\": [\"17145768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"p18(Ink4c) functionally collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers; bronchioalveolar stem cells are further expanded in p18(-/-);Men1(+/-) compound mice compared to single mutants, and Rb phosphorylation at CDK2 and CDK4/CDK6 sites is significantly increased.\",\n      \"method\": \"Double-mutant mouse model, lung tumor characterization, Rb phosphorylation analysis, bronchioalveolar stem cell quantification\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with molecular pathway validation, replicates collaboration between p18 and Men1 seen in endocrine tissues\",\n      \"pmids\": [\"17409423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Menin directly interacts with PRMT5, a negative regulator of gene transcription. Menin recruits PRMT5 to the Gas1 gene promoter, increases repressive histone arginine symmetric dimethylation (H4R3m2s), and suppresses Gas1 expression, thereby epigenetically suppressing Hedgehog signaling. MEN1 disease-related menin mutants show reduced PRMT5 binding and fail to impart the H4R3m2s mark at the Gas1 promoter.\",\n      \"method\": \"Co-immunoprecipitation, ChIP assay, histone methylation analysis, luciferase reporter, pharmacologic Hedgehog inhibition in MEN1 mouse tumors, mutant menin binding analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP, functional reporter, disease mutant validation, and pharmacologic rescue in vivo — multiple orthogonal methods\",\n      \"pmids\": [\"23580576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CDK4, but not CDK2, is required for MEN1-dependent tumorigenesis in pituitary and pancreatic islets. Men1(+/-);Cdk4(-/-) mice do not develop tumors and remain hypoplastic, while Men1(+/-);Cdk2(-/-) mice show normal tumorigenesis. CDK4 knockdown in INS-1 insulinoma cells inhibits glucose-stimulated cell cycle progression with decreased RB phosphorylation at Ser780, while CDK2 knockdown has minimal effect.\",\n      \"method\": \"Double-mutant mouse epistasis, tumor incidence analysis, LOH analysis, CDK4/CDK2 knockdown in insulinoma cells, RB phosphorylation western blotting\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in two cell types in vivo, confirmed by cell-line RNAi with phospho-specific RB readout, multiple orthogonal methods\",\n      \"pmids\": [\"24531709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Alpha cell-specific Men1 ablation in mice leads to the transdifferentiation of glucagon-expressing cells into insulinoma cells, demonstrating that menin regulates the plasticity of differentiated pancreatic alpha cells in vivo. Genetic cell lineage tracing confirmed that insulinoma cells were directly derived from glucagon-expressing cells.\",\n      \"method\": \"Conditional Men1 knockout (GluCre-loxP), genetic cell lineage tracing, immunohistochemistry, transcription factor expression analysis\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with genetic lineage tracing providing direct mechanistic evidence of cell fate change\",\n      \"pmids\": [\"20138042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of menin activates DNMT1 by activating retinoblastoma-binding protein 5 (Rbbp5), leading to global DNA hypermethylation. This aberrant methylation inactivates Sox regulatory genes and aberrantly activates Wnt/β-catenin signaling. Demonstrated in MEN1 parathyroid tumors, Men1 knockout mice, and Men1-null MEF cell lines.\",\n      \"method\": \"Genome-wide methylation analysis, Men1 KO mouse and MEF cell lines, DNMT1 activity assay, Rbbp5 pathway analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide methylation plus mechanistic pathway analysis in multiple model systems, single lab\",\n      \"pmids\": [\"26871472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Men1 loss in the exocrine pancreas causes increased injury and impaired regeneration following acute caerulein-induced pancreatitis. Men1 protein is stabilized in response to pancreatic insult. Loss of Men1 is associated with overexpression of pro-inflammatory JunD target genes, suggesting menin suppresses JunD activity in the exocrine pancreas. Men1 loss also significantly accelerates mutant Kras-dependent pancreatic oncogenesis.\",\n      \"method\": \"Conditional Men1 KO mouse model, caerulein pancreatitis model, KrasG12D compound mouse model, Men1 protein stability assay, JunD target gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with mechanistic pathway readout (JunD targets), protein stabilization assay, and oncogenic cooperation model in vivo, multiple independent experiments\",\n      \"pmids\": [\"32156729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Somatic mutations at the menin-MLL1 interface (revumenib-menin interface) confer clinical resistance to menin inhibition. These mutations attenuate drug-target binding via structural perturbations that impact small-molecule binding but not the natural MLL1 interaction, and prevent inhibitor-induced eviction of menin and MLL1 from chromatin.\",\n      \"method\": \"Clinical resistance mutation sequencing, xenograft models, base-editor screen, structural perturbation analysis, chromatin immunoprecipitation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clinical genomics plus xenograft validation plus unbiased base-editor screen plus ChIP; multiple independent and orthogonal methods\",\n      \"pmids\": [\"36922589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MEN1 protein is degraded via the neddylation pathway and CUL4B-DCAF7-mediated ubiquitination. DCAF7 binds menin and catalyzes its ubiquitination, leading to proteasomal degradation. Suppression of neddylation (MLN4924) or DCAF7 knockdown induces MEN1 accumulation, and the oncogenic effects of DCAF7 loss are counteracted by simultaneous MEN1 knockdown.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, RNAi knockdown, neddylation inhibitor (MLN4924), in vitro and in vivo rescue experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vitro ubiquitination assay, genetic rescue in vivo, multiple orthogonal methods in single study\",\n      \"pmids\": [\"36939378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MEN1 knockout redistributes MLL1 chromatin occupancy, increasing H3K4me3 at repetitive genomic regions, activating double-stranded RNA expression, and increasing immune cell infiltration. Pharmacological inhibition of the menin-MLL interaction reduces tumor growth in a CD8+ T cell-dependent manner, revealing a tumor microenvironment-dependent function of MEN1.\",\n      \"method\": \"In vivo CRISPR-Cas9 screen in xenograft vs. 2D culture, ChIP-seq (H3K4me3), dsRNA expression analysis, immune cell profiling, pharmacologic menin-MLL inhibition in immunocompetent and immunodeficient mice, CD8+ T cell depletion\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo CRISPR screen, ChIP-seq, mechanistic immune profiling, and pharmacologic validation with cell-depletion controls — multiple orthogonal methods\",\n      \"pmids\": [\"39227744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MEN1, encoding menin, is a component of a histone methyltransferase complex; 44% of pancreatic neuroendocrine tumors carry somatic inactivating mutations in MEN1, establishing menin as a chromatin remodeling factor whose loss contributes to PanNET tumorigenesis.\",\n      \"method\": \"Exome sequencing of 68 PanNETs, mutation screening\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — large-scale somatic mutation survey identifying MEN1 as chromatin remodeler component, single method (sequencing), but highly replicated across many tumors\",\n      \"pmids\": [\"21252315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MEN1 deficiency in a KrasG12D lung cancer mouse model leads to accumulation of DNA damage and antagonizes oncogenic Kras-induced senescence and the epithelial-to-mesenchymal transition, resulting in neuroendocrine differentiation of lung cancer.\",\n      \"method\": \"ATII-specific KrasG12D/Men1-/- genetically engineered mouse model, DNA damage markers, senescence assays, EMT marker analysis, NE differentiation markers\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO model with multiple molecular readouts (DNA damage, senescence, EMT, NE markers), single lab\",\n      \"pmids\": [\"32081882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In Men1(+/-)Rb(+/-) compound mice, loss of the remaining wild-type Men1 and Rb alleles is mutually exclusive in all tumors, indicating that Men1 and Rb act in the same pathway. Down-regulation of Men1 targets p18 and p27 and increased phospho-Rb were observed in Men1-deficient pheochromocytomas. RNAi knockdown of Men1 increased apoptosis in Rb-deficient medullary thyroid carcinoma cells, revealing cell lineage-specific interactions.\",\n      \"method\": \"Compound mutant mouse model, LOH analysis, p18/p27 expression analysis, phospho-Rb western blot, RNAi knockdown in cell lines\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo epistasis with molecular pathway validation (p18, p27, phospho-Rb), single lab\",\n      \"pmids\": [\"17893233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GFAP-directed Men1 inactivation in glial cells induces neuroendocrine differentiation and tumorigenesis (pancreatic NETs, prolactinomas). Men1 deletion causes loss of glial progenitor markers and gain of neuroendocrine genes. Co-deletion of Kif3a (Hedgehog mediator) attenuates neuroendocrine hyperplasia, implicating Hedgehog signaling downstream of Men1 in glial-to-neuroendocrine reprogramming.\",\n      \"method\": \"Conditional Men1 KO (GFAP-Cre), Cre lineage tracing (tdTomato), gene expression analysis, double KO (Kif3a/Men1 and Sox10/Men1)\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with lineage tracing and genetic epistasis, single lab\",\n      \"pmids\": [\"35835391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Menin promotes ferroptosis in pancreatic neuroendocrine tumor cells by inhibiting the mTOR-SCD1 axis. MEN1 overexpression suppresses mTOR signaling and reduces SCD1 expression; oleic acid (an SCD1 metabolite) rescues lipid peroxidation caused by MEN1 overexpression. MEN1-overexpressing cells are more sensitive to the mTOR inhibitor everolimus.\",\n      \"method\": \"Targeted metabolomics, MEN1 overexpression/knockdown in pNET cells, mTOR pathway analysis, SCD1 expression assay, ferroptosis assays, lipid peroxidation measurement, everolimus sensitivity assay\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple molecular assays linking MEN1 to mTOR-SCD1-ferroptosis pathway, single lab\",\n      \"pmids\": [\"36604142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MEN1/Menin suppresses the PI3K/Akt/mTOR pathway in bovine mammary epithelial cells; menin overexpression significantly suppresses mTOR pathway factors and milk protein κ-casein, while MEN1 knockdown increases them. Menin also negatively modulates responses to prolactin and insulin upstream of mTOR.\",\n      \"method\": \"MEN1 overexpression and knockdown in bovine mammary epithelial cells and tissues, mTOR pathway western blotting, milk protein (κ-casein) expression analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell type, gain/loss-of-function with pathway markers but no rescue experiment or structural validation\",\n      \"pmids\": [\"28710500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A 596 bp deletion in the 5' UTR of MEN1 including the core promoter causes significant reductions (37-fold in HEK293, 16-fold in BON-1) in promoter-driven luciferase expression, and 84% and 88% reductions in MEN1 mRNA and menin protein, respectively, in patient-derived lymphoblastoid cells, establishing a regulatory role for the MEN1 5' UTR in menin expression.\",\n      \"method\": \"Luciferase reporter assay, qRT-PCR, Western blotting in patient-derived EBV-transformed lymphoblastoid cells\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay complemented by endogenous mRNA and protein measurement in patient cells, single lab, two orthogonal methods\",\n      \"pmids\": [\"32780883\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Menin is a predominantly nuclear scaffold protein (with C-terminal NLS sequences) that functions as a tumor suppressor by: (1) forming part of MLL1/MLL2 histone H3K4 methyltransferase complexes to regulate chromatin and transcription; (2) recruiting PRMT5 to gene promoters (e.g., Gas1) to impose repressive H4R3m2s marks and suppress Hedgehog signaling; (3) repressing JunD-mediated transcription; (4) maintaining CDK inhibitor expression (p18Ink4c, p27Kip1) to restrain G1-to-S cell cycle progression via CDK4 and Rb; (5) suppressing the mTOR pathway to promote ferroptosis; (6) regulating exocrine pancreas homeostasis partly through restraint of JunD target genes; and (7) maintaining chromatin occupancy patterns such that its loss redistributes MLL1 to repetitive elements and activates dsRNA/immune responses; menin protein stability is controlled post-translationally by CUL4B-DCAF7-mediated ubiquitination and neddylation-dependent proteasomal degradation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Menin, encoded by MEN1, is a predominantly nuclear scaffold protein that acts as a tumor suppressor by coordinating chromatin-based transcriptional control with cell cycle restraint, and its inactivation drives neuroendocrine tumorigenesis [#0, #13]. It restrains the G0/G1-to-S transition by maintaining expression of the CDK inhibitors p18(Ink4c) and p27(Kip1); loss of menin elevates CDK2 activity and accelerates S-phase entry, and complementation with wild-type menin reverses this [#2]. Genetic epistasis establishes that p18(Ink4c) and menin act in the same pathway to suppress neuroendocrine and lung tumors through control of Rb phosphorylation, with CDK4 — not CDK2 — being the kinase required for MEN1-dependent pituitary and islet tumorigenesis [#3, #4, #6]; menin and Rb likewise operate in a shared, lineage-specific pathway [#15]. Menin enforces transcriptional programs through chromatin: it recruits PRMT5 to target promoters such as Gas1 to deposit repressive H4R3me2s marks and suppress Hedgehog signaling, and disease-associated menin mutants fail to bind PRMT5 or impose this mark [#5, #16]; it also represses JunD-mediated transcription, a function conserved to zebrafish [#1]. Within the MLL1 histone H3K4 methyltransferase complex, menin maintains normal chromatin occupancy, and its loss redistributes MLL1 to repetitive elements, raising H3K4me3 there, inducing double-stranded RNA expression and immune infiltration, such that menin-MLL inhibition restrains tumors in a CD8+ T cell-dependent manner [#12]. Menin loss also restrains differentiated-cell plasticity, permitting transdifferentiation of pancreatic alpha cells into insulinoma cells and reprogramming of glial cells toward neuroendocrine fates [#7, #16]. Menin protein abundance is set post-translationally by CUL4B-DCAF7-mediated, neddylation-dependent ubiquitination and proteasomal degradation, and is stabilized in response to tissue injury [#9, #11]. Inactivating somatic MEN1 mutations and a 5'UTR/core-promoter deletion that collapses menin expression underlie pancreatic neuroendocrine and MEN1-related tumors [#13, #19], and clinical resistance to menin inhibitors arises from mutations at the menin-MLL1 drug interface that block inhibitor-induced eviction of menin and MLL1 from chromatin without disrupting the native MLL1 interaction [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established where menin acts in the cell, defining it as a nuclear protein with discrete C-terminal localization signals — a prerequisite for any chromatin/transcriptional model.\",\n      \"evidence\": \"Immunofluorescence, subcellular fractionation, and GFP deletion mapping\",\n      \"pmids\": [\"9465067\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define molecular activity or binding partners\", \"NLS mapping does not address cytoplasmic functions later reported\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified a conserved transcriptional output for menin by showing it binds JunD and represses JunD-driven transcription, the first specific mechanistic activity assigned.\",\n      \"evidence\": \"Protein binding and reporter assays in a zebrafish ortholog system\",\n      \"pmids\": [\"10818209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ortholog/reporter system, not endogenous human loci\", \"Does not establish how JunD repression links to tumor suppression\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected menin loss to cell cycle deregulation, showing it maintains CDK inhibitors p18/p27 to restrain S-phase entry, providing a proliferative mechanism for tumor suppression.\",\n      \"evidence\": \"Conditional Men1 knockout in MEFs and islets with cell cycle, CDK2, and rescue analyses\",\n      \"pmids\": [\"16740708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve which downstream CDK is rate-limiting in vivo\", \"Mechanism by which menin maintains p18/p27 transcription not defined here\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Pinpointed p18(Ink4c) as the genetically relevant collaborator with menin in the same Rb pathway, distinguishing it from p27 in neuroendocrine tumor suppression.\",\n      \"evidence\": \"Double-mutant mouse epistasis, Rb phosphorylation, and LOH analysis\",\n      \"pmids\": [\"17145768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue specificity of p18 vs p27 contribution not fully explained\", \"Does not identify the CDK enforcing the Rb phenotype\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended the menin-p18 collaboration to lung stem cell expansion and NSCLC, showing the pathway operates beyond endocrine tissues.\",\n      \"evidence\": \"p18(-/-);Men1(+/-) mouse lung tumor model with stem cell quantification and Rb phosphorylation\",\n      \"pmids\": [\"17409423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define menin's molecular role in stem cell compartment\", \"Relative contribution of CDK2 vs CDK4/6 sites not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Placed Men1 and Rb in the same pathway via mutually exclusive allele loss and revealed lineage-specific consequences of menin loss.\",\n      \"evidence\": \"Men1;Rb compound mouse model, LOH, phospho-Rb, and RNAi in tumor cells\",\n      \"pmids\": [\"17893233\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of cell-lineage-specific apoptosis on Men1 knockdown unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated that menin restrains differentiated cell plasticity, with its loss permitting alpha-to-beta cell transdifferentiation into insulinoma — a fate-control rather than purely proliferative role.\",\n      \"evidence\": \"Alpha cell-specific Men1 knockout with genetic lineage tracing\",\n      \"pmids\": [\"20138042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mediators of the transdifferentiation not identified\", \"Does not link fate change to specific menin chromatin targets\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established the clinical and biological weight of MEN1 loss by showing somatic inactivating mutations in ~44% of PanNETs and framing menin as a chromatin/HMT-complex component.\",\n      \"evidence\": \"Exome sequencing of 68 pancreatic neuroendocrine tumors\",\n      \"pmids\": [\"21252315\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Sequencing alone does not demonstrate mechanism\", \"Does not show which chromatin function is lost in tumors\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a direct epigenetic-repressive mechanism: menin recruits PRMT5 to deposit H4R3me2s and silence Hedgehog target Gas1, with disease mutants failing this — linking chromatin marks to a tumorigenic pathway.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP, reporter assays, mutant binding, and pharmacologic Hedgehog inhibition in MEN1 tumors\",\n      \"pmids\": [\"23580576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide extent of PRMT5 recruitment not mapped\", \"Relationship between PRMT5 and MLL1 complexes not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolved which CDK is rate-limiting, showing CDK4 (not CDK2) is required for MEN1-dependent pituitary and islet tumorigenesis, refining therapeutic targeting downstream of menin.\",\n      \"evidence\": \"Men1;Cdk4 and Men1;Cdk2 double-mutant mice plus CDK knockdown in insulinoma cells with phospho-RB readout\",\n      \"pmids\": [\"24531709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not reconcile with earlier CDK2 activity findings across tissues\", \"Mechanism connecting menin loss to CDK4 activation not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Proposed a DNA-methylation arm of menin tumor suppression, where loss activates DNMT1 via Rbbp5, causing hypermethylation that silences Sox genes and activates Wnt/beta-catenin.\",\n      \"evidence\": \"Genome-wide methylation analysis in MEN1 tumors, Men1 KO mice and MEFs, DNMT1 activity assays\",\n      \"pmids\": [\"26871472\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; mechanism of Rbbp5-DNMT1 activation needs orthogonal validation\", \"Causal link between hypermethylation and Wnt activation not fully established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed menin governs exocrine pancreas injury response and regeneration partly via JunD target restraint, and cooperates with mutant Kras in oncogenesis, with menin protein stabilized upon insult.\",\n      \"evidence\": \"Conditional Men1 KO with caerulein pancreatitis, KrasG12D compound model, and protein stability assay\",\n      \"pmids\": [\"32156729\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How injury stabilizes menin protein not mechanistically defined\", \"Direct JunD target set in exocrine pancreas not enumerated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed that menin loss antagonizes Kras-induced senescence and EMT and drives neuroendocrine differentiation of lung cancer, with DNA damage accumulation.\",\n      \"evidence\": \"ATII KrasG12D/Men1-/- mouse model with DNA damage, senescence, EMT and NE marker analysis\",\n      \"pmids\": [\"32081882\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking menin loss to NE reprogramming not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that the MEN1 5'UTR/core promoter is required for menin expression, identifying a regulatory cause of menin loss beyond coding mutations.\",\n      \"evidence\": \"Luciferase reporter, qRT-PCR, and Western blotting in patient-derived lymphoblastoid cells\",\n      \"pmids\": [\"32780883\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factors acting at this promoter not identified\", \"Single patient-derived deletion characterized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified a metabolic tumor-suppressive function in which menin promotes ferroptosis by inhibiting the mTOR-SCD1 axis in pNET cells.\",\n      \"evidence\": \"Metabolomics, MEN1 gain/loss, mTOR/SCD1 readouts, lipid peroxidation, and oleic acid/everolimus rescue\",\n      \"pmids\": [\"36604142\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How nuclear menin suppresses mTOR mechanistically unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed menin loss reprograms glial cells toward neuroendocrine fates via downstream Hedgehog signaling, linking fate control to the PRMT5/Hedgehog axis.\",\n      \"evidence\": \"GFAP-Cre Men1 KO with lineage tracing and Kif3a/Sox10 genetic epistasis\",\n      \"pmids\": [\"35835391\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct chromatin targets driving reprogramming not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the post-translational control of menin abundance, identifying CUL4B-DCAF7 as the E3 machinery and neddylation as required for its degradation.\",\n      \"evidence\": \"Reciprocal Co-IP, in vitro ubiquitination, RNAi, MLN4924, and in vivo genetic rescue\",\n      \"pmids\": [\"36939378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals triggering DCAF7-mediated degradation not defined\", \"Site(s) of menin ubiquitination not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Explained clinical menin-inhibitor resistance, showing mutations at the menin-MLL1 drug interface block inhibitor-induced chromatin eviction without disrupting the native interaction.\",\n      \"evidence\": \"Clinical resistance sequencing, xenografts, base-editor screen, structural and ChIP analysis\",\n      \"pmids\": [\"36922589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Strategies to overcome interface resistance not established\", \"Does not address resistance arising outside the interface\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Uncovered a tumor microenvironment-dependent function: menin loss redistributes MLL1, activates dsRNA/immune responses, and renders tumors sensitive to menin-MLL inhibition via CD8+ T cells.\",\n      \"evidence\": \"In vivo CRISPR screen, H3K4me3 ChIP-seq, dsRNA and immune profiling, and immune-competent vs depleted mouse models\",\n      \"pmids\": [\"39227744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism restraining MLL1 redistribution by menin not detailed\", \"Generalizability across tumor types not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How menin's distinct nuclear activities — MLL1 H3K4 methylation, PRMT5 recruitment, JunD repression, and DNMT1 regulation — are integrated on chromatin, and how these connect to cytoplasmic mTOR/ferroptosis control, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking menin's repressive and activating chromatin functions\", \"Mechanism by which a nuclear scaffold modulates mTOR signaling unclear\", \"Cell-type determinants of menin's opposing roles not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 5, 12]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [5, 11]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [5, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [5, 12, 13]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 5, 8]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 3, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 13, 19]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [\"MLL1 H3K4 methyltransferase complex\", \"CUL4B-DCAF7 E3 ubiquitin ligase complex\"],\n    \"partners\": [\"MLL1\", \"PRMT5\", \"JunD\", \"DCAF7\", \"CUL4B\", \"Rbbp5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}